Pharming Group (NASDAQ:PHAR) Shares Gap Up – What’s Next?

Pharming Group (NASDAQ:PHAR)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $9.38, but opened at $9.67. Pharming Group shares last traded at $9.67, with a volume of 513 shares traded.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Oppenheimer reduced their price objective on shares of Pharming Group from $31.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, October 28th. Jefferies Financial Group initiated coverage on shares of Pharming Group in a report on Monday, December 9th. They issued a “buy” rating and a $14.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and set a $37.00 target price on shares of Pharming Group in a research report on Tuesday, December 17th.

Pharming Group Trading Up 5.1 %

The firm’s 50-day simple moving average is $8.86 and its 200-day simple moving average is $8.38. The firm has a market capitalization of $678.98 million, a P/E ratio of -38.50 and a beta of -0.08. The company has a quick ratio of 2.76, a current ratio of 3.53 and a debt-to-equity ratio of 0.41.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 47,997 shares of the company’s stock after buying an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. Institutional investors own 0.03% of the company’s stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.